Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[The pharmacogenetics of vitamin K antagonists: still a matter for discussion].

La Revue de medecine interne - 1 May 2010

Moreau C, Siguret V, Loriot M-A

Abstract excerpt

The use of vitamin K antagonists (VKA) is challenging because of their narrow therapeutic index and a high bleeding risk. These drugs are widely prescribed for the prophylaxis and treatment of many thrombo-embolic disorders. The management of patients with VKA represents a public health problem according to the high number of deaths and hospitalizations in relation to hemorrhagic complications. Monitoring is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aryl Hydrocarbon Hydroxylases
Share to Cytochrome P-450 CYP2C9
Share to Hemorrhage

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mixed Function Oxygenases

Share to Pharmacogenetics

Share to Thromboembolism

Share to Vitamin K

Share to Vitamin K Epoxide Reductases

Source

Identifiers

PMID: 20362363
DOI: 10.1016/j.revmed.2009.07.014

Genes

VKORC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[The pharmacogenetics of vitamin K antagonists: still a matter for discussion].PMID 20362363Read ↗

Pharmacogenetics aspects of oral anticoagulants therapy.Semantic proximity Read ↗

[Impact of pharmacogenetics on interindividual variability in the response to vitamin K antagonist therapy].Semantic proximity Read ↗

[Oral anticoagulation and pharmacogenetics: importance in the clinical setting].Semantic proximity Read ↗

Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles.Semantic proximity Read ↗

[Pharmacogenomics of vitamin K antagonists].Semantic proximity Read ↗

[Genetic determinants of response to vitamin K antagonists].Semantic proximity Read ↗

[Pharmacogenetic algorithms for predicting the appropriate dose of vitamin K antagonists: are they still useful?].Semantic proximity Read ↗

Bleeding predictors in patients following venous thromboembolism treated with vitamin K antagonists: Association with increased number of single nucleotide polymorphisms.Semantic proximity Read ↗

Pharmacogenetics role in the safety of acenocoumarol therapy.Semantic proximity Read ↗

Genetic polymorphisms and major bleeding risk during vitamin K antagonists treatment: The BLEEDS case-cohort.Semantic proximity Read ↗

Pharmacogenetics of warfarin: current status and future challenges.Semantic proximity Read ↗

A Pharmacogenetically Guided Acenocoumarol Dosing Algorithm for Chilean Patients: A Discovery Cohort StudySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.